According to data from the Central Cancer Registry released in 2024, the five-year relative survival rate of gastric cancer ...
The European Society for Medical Oncology "Living Guideline" for Gastric Cancer suggests that narrow-band imaging or ...
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments ...
Use of DNA polymerase η protein expression to predict treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. Combined treatment of ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...